Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Sponsor
Takeda
Study ID
NCT04804813
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a survey in Japan of Cabozantinib tablets used to treat people with a type of kidney cancer called renal cell carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with renal cell carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 26 weeks.

Key Dates

Start date
Mar 29, 2021
Status verified
Mar 2025
Primary completion
Jul 25, 2024
Completion
Jul 25, 2024

Study Design

Enrollment
388 participants (actual)

Arms

  • Arm: Cabozantinib 60 mg
    Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 26 weeks. Participants received interventions as part of routine medical care.

Primary Outcome Measure

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE) [ Time Frame: Up to 26 weeks ]

Related Studies